Search

everythinglearnresearchcommunity

for

Search:↓

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Low testosterone can cause a heart rhythm problem in men, but fixing it can prevent the issue.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

Finasteride may improve prostate cancer treatment outcomes.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

The normal human prostate does not significantly affect blood DHT levels.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.

New treatments for hair loss should target eight main causes and use specific plant compounds and peptides for better results.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Hirsutism is often caused by high male hormone levels and can be treated with lifestyle changes and medications.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

Kennedy's disease leads to muscle weakness without a cure, but exercise and managing symptoms may help patients live a normal lifespan.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

Testosterone therapy improves physical function, strength, and body composition in older men with low testosterone levels.

Men with androgenetic alopecia and hypertension may experience more severe COVID-19.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

A new compound, 3a, effectively fights prostate cancer better than finasteride.